Navigation Links
Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response
Date:11/30/2009

NEW YORK, Nov. 30 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response

http://www.reportlinker.com/p0165600/Inflammatory-Disorders-Therapies-That-Suppress-or-Balance-the-Immune-Response.html

The human immune system can go awry, either attacking an individual body or producing an exaggerated response to a foreign substance that is normally benign. In these situations, immunotherapies are needed to balance or suppress the unwarranted immune response. In this report:

  • Approximately 400 product candidates and development programs are identified.
  • Current and emerging therapies for selected autoimmune or inflammatory disorders and prevention of organ transplant rejection, directed against a wide range of putative targets, are summarized.
  • Specifically, more than 250 emerging autoimmune disease therapies, 80 asthma therapies in development, and 50+ therapy candidates for allergies are covered.
  • The strategic consequences of intense competition in a crowded product space are considered.

Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response reviews the problems of insufficient efficacy, side effects, and adverse events associated with the small-molecule and biological drugs available today to treat these disorders. These observations have led to an interest in identifying ways to balance the immune reaction, to suppress the part of the immune response that is causing the disease, while maintaining or enhancing other aspects of the immune system. This report identifies nearly 400 ongoing product candidates and development programs in these indication areas. The companies active in these areas range from multinational pharmaceutical companies with a number of active programs to small boutique start-ups working on a very defined topic.

CHAPTER 1: INTRODUCTION

1.1. The Immune System

1.2. Scope of the Report

CHAPTER 2: REVIEW OF MAJOR DISEASES/ CONDITIONS TARGETED BY NEW AND/OR EMERGING IMMUNOTHERAPIES AND VACCINES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM

2.1. Major Autoimmune Diseases

Rheumatoid Arthritis

Type 1 Diabetes Mellitus

Inflammatory Bowel Disease--Crohn's Disease and Ulcerative Colitis

Multiple Sclerosis

Psoriasis

Psoriatic Arthritis

Systemic Lupus Erythematosus

2.2. Asthma

2.3. Allergies

2.4. Immune Suppression to Prevent

Rejection of Organ Transplants

CHAPTER 3: CURRENT PHARMACOLOGICAL TREATMENT OPTIONS

3.1. Major Autoimmune Diseases

Rheumatoid Arthritis

Nonsteroidal Anti-inflammatory Drugs

(NSAIDs)

Disease-Modifying Antirheumatic

Drugs (DMARDs)

Corticosteroids

Biological Response Modifiers

Type 1 Diabetes Mellitus

Inflammatory Bowel Disease--Crohn's Disease and Ulcerative Colitis

Multiple Sclerosis

Interferon-beta

Copaxone (glatiramer acetate)

Novantrone (mitoxantrone)

Tysabri (natalizumab)

Psoriasis

Psoriatic Arthritis

Systemic Lupus Erythematosus

3.2. Asthma

3.3. Allergies

3.4. Immune Suppression to Prevent Rejection of Organ Transplants

CHAPTER 4: CURRENT AND EMERGING APPROACHES TO SUPPRESS OR BALANCE THE IMMUNE SYSTEM FOR PREVENTION AND TREATMENT OF DISEASE

CHAPTER 5: EMERGING THERAPIES IN DEVELOPMENT FOR TREATMENT OF MAJOR AUTOIMMUNE DISEASES

5.1. Introduction

5.2. Abbott Laboratories

5.3. Biogen Idec

5.4. AstraZeneca

5.5. Bristol-Myers Squibb

5.6. Centocor Ortho Biotech

5.7. Centocor Ortho Biotech and Schering-Plough

5.8. Diamyd Medical

5.9. Eli Lilly and BioMS Medical

5.10. Eli Lilly and MacroGenics

5.11. Genzyme and Bayer

5.12. GlaxoSmithKline and Genmab

5.13. GlaxoSmithKline and Human Genome Sciences

5.14. GlaxoSmithKline and Tolerx

5.15. GlaxoSmithKline (Selected Additional Product Candidates and Research)

5.16. Isotechnika

5.17. Merck Serono and ZymoGenetics

5.18. Merck Serono

5.19. Novartis

Multiple Sclerosis

Rheumatoid Arthritis

Psoriasis

5.20. Pfizer

5.21. Roche and Chugai Pharmaceutical

5.22. Roche and Genentech (A Wholly-Owned Member of the Roche Group)

5.23. Sanofi-Aventis

5.24. Takeda Pharmaceutical and Millennium Pharmaceuticals

5.25. Teva Pharmaceutical Industries and Active Biotech

5.26. UCB

CHAPTER 6: EMERGING THERAPIES FOR TREATMENT OF ASTHMA

6.1. Pipeline Overview

6.2. Abbott Laboratories and SkyePharma (Also Mundipharma and Kyorin)

6.3. Aerovance

6.4. Amgen

6.5. AstraZeneca

6.6. Ception Therapeutics

6.7. Genentech

6.8. GlaxoSmithKline

6.9. Icagen

6.10. MediciNova

6.11. Pfizer

6.12. Schering-Plough and Novartis

6.13. Topigen Pharmaceuticals

6.14. Wyeth

CHAPTER 7: SELECTED EXAMPLES OF EMERGING THERAPIES FOR TREATMENT OF ALLERGIES

7.1. Introduction

7.2. ALK-Abello and Schering-Plough

7.3. Allergy Therapeutics

7.4. Ception Therapeutics

7.5. Cytos Biotechnology

7.6. Greer Laboratories

7.7. Stallergenes

CHAPTER 8: IMMUNOTHERAPIES IN DEVELOPMENT FOR PREVENTING REJECTION OF ORGAN TRANSPLANTS

8.1. Introduction

8.2. APT Pharmaceuticals

8.3. Astellas Pharma

8.4. Bristol-Myers Squibb

8.5. Isotechnika

8.6. Novartis

8.7. Pfizer

CHAPTER 9: BUSINESS CONSIDERATIONS --THERAPIES THAT SUPPRESS OR BALANCE THE IMMUNE SYSTEM

9.1. Current Market and Market Potential

9.2. Competition

9.3. Strong Interest on the Part of Major Pharmaceutical Companies

9.4. Agreements and Mergers/Acquisitions

9.5. Other Major Challenges and Hurdles Being Faced by Companies

Competition

Potential Need for Personalized Medicine in at Least Certain Situations

Targeted Patient Populations

CHAPTER 10: THOUGHT LEADER INTERVIEWS

10.1. David W. Pritchard, President and Chief Executive Officer, KaloBios

10.2. Randall C. Schatzman, PhD, President and Chief Executive Officer, Alder Biopharmaceuticals

10.3. Louis Vaickus, MD, Chief Medical Officer, Tolerx

10.4. Eric H. Zanelli, PhD, Vice President, Research, Peptimmune

REFERENCES

COMPANY INDEX WITH WEB ADDRESSES

To order this report:

Therapy Industry: Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response

More Market Research Report


Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015
2. Reportlinker Adds Mammography Equipment - A Global Market Perspective
3. Reportlinker Adds Pain Management - Global Trends
4. Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis
5. Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015
6. Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015
7. Reportlinker Adds U.S. Market for PACS and EMR
8. Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective
9. Reportlinker Adds Holter Monitoring Systems - A Global Market Review
10. Reportlinker Adds Medical Nonwoven Disposables - A Worldwide Market Review
11. Reportlinker Adds Anesthesia Disposables - A World Market Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
(Date:4/28/2016)... April 28, 2016   Click here for ... Inc. (NYSE: DPLO), the nation,s largest independent specialty ... definitive agreement to acquire Valley Campus Pharmacy, Inc., ... a leading specialty pharmacy that provides individualized patient ... . In 2015, TNH generated approximately $400 ...
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... With the opioid epidemic now ... excessive levels of alcohol use. Alcohol and its misuse causes long-term consequences for ... the susceptibility to strokes in those 65 years and older. In addition, there ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... process that selects DNA or RNA from a random library of sequences depending ... used as drugs or diagnostic agents. SELEX selection is commonly performed using filters, ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... hired award-winning creative director Joe Ferrazano to serve in the newly created position ... will be overseeing the agency’s creative efforts in the Chicago and LA offices. ...
(Date:5/3/2016)... ... ... Elizabeth Murray has always loved walking one to two miles a day. ... and one on her arm. But she got to the point where she could ... , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, where ...
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the car ... anxiety. "Pet owners often think anxiety only manifests itself as trembling or ‘tail ... ways, and there’s things that be done about it,” says Dr. Jim Lowe, technical ...
Breaking Medicine News(10 mins):